Concurrence of prothrombin nonneutralizing antibody and factor XI neutralizing inhibitor in lupus anticoagulant positive patient.

IF 1.2 4区 医学 Q4 HEMATOLOGY
Blood Coagulation & Fibrinolysis Pub Date : 2025-06-01 Epub Date: 2025-04-03 DOI:10.1097/MBC.0000000000001360
Ju Hyeong Lee, Ja-Yoon Gu, Junshik Hong, Kwon-Wook Joo, Eun Young Lee, Hyun Kyung Kim
{"title":"Concurrence of prothrombin nonneutralizing antibody and factor XI neutralizing inhibitor in lupus anticoagulant positive patient.","authors":"Ju Hyeong Lee, Ja-Yoon Gu, Junshik Hong, Kwon-Wook Joo, Eun Young Lee, Hyun Kyung Kim","doi":"10.1097/MBC.0000000000001360","DOIUrl":null,"url":null,"abstract":"<p><p>Isolated prothrombin antibody or isolated factor XI inhibitor have been reported separately in lupus-anticoagulant positive patients. We report the first case of a lupus-anticoagulant positive patient that both simultaneously occurred. A 30-year-old man with a history of systemic lupus erythematosus was positive for lupus-anticoagulant. He exhibited significantly high bleeding score compared to previous reports of lupus-anticoagulant positive patients with isolated prothrombin or factor XI deficiency. Examination via one-stage clotting assays revealed decreased levels of both prothrombin and factor XI. Factor parallelism was proven for prothrombin but not for factor XI. The factor XI inhibitor was quantified at 2.1 Bethesda units in the Bethesda assay, and antiprothrombin nonneutralizing antibody tested positive in ELISA. This study suggests that the concurrence of prothrombin nonneutralizing antibody and factor XI neutralizing inhibitor can aggravate bleeding tendency synergistically in lupus-anticoagulant positive patient. Bethesda assay or ELISA may be considered depending on the factor-parallelism in one-stage clotting assay.</p>","PeriodicalId":8992,"journal":{"name":"Blood Coagulation & Fibrinolysis","volume":" ","pages":"130-133"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Coagulation & Fibrinolysis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MBC.0000000000001360","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/3 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Isolated prothrombin antibody or isolated factor XI inhibitor have been reported separately in lupus-anticoagulant positive patients. We report the first case of a lupus-anticoagulant positive patient that both simultaneously occurred. A 30-year-old man with a history of systemic lupus erythematosus was positive for lupus-anticoagulant. He exhibited significantly high bleeding score compared to previous reports of lupus-anticoagulant positive patients with isolated prothrombin or factor XI deficiency. Examination via one-stage clotting assays revealed decreased levels of both prothrombin and factor XI. Factor parallelism was proven for prothrombin but not for factor XI. The factor XI inhibitor was quantified at 2.1 Bethesda units in the Bethesda assay, and antiprothrombin nonneutralizing antibody tested positive in ELISA. This study suggests that the concurrence of prothrombin nonneutralizing antibody and factor XI neutralizing inhibitor can aggravate bleeding tendency synergistically in lupus-anticoagulant positive patient. Bethesda assay or ELISA may be considered depending on the factor-parallelism in one-stage clotting assay.

狼疮抗凝阳性患者凝血酶原非中和抗体与因子XI中和抑制剂的并发。
分离凝血酶原抗体或分离因子XI抑制剂已分别报道狼疮抗凝血阳性患者。我们报告第一例狼疮-抗凝血阳性患者同时发生。30岁男性,系统性红斑狼疮病史,狼疮抗凝血阳性。与先前报道的红斑狼疮抗凝血阳性且分离凝血酶原或因子XI缺乏的患者相比,他表现出明显的高出血评分。通过一期凝血检测显示凝血酶原和因子XI水平降低。凝血酶原存在因子平行性,而因子XI不存在。Bethesda法测定因子XI抑制剂为2.1 Bethesda单位,ELISA检测抗凝血酶原非中和抗体阳性。本研究提示凝血酶原非中和抗体与因子XI中和抑制剂同时使用可协同加重狼疮抗凝阳性患者的出血倾向。贝塞斯达测定法或酶联免疫吸附试验可考虑取决于因素平行在一个阶段的凝血测定。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
111
审稿时长
4-8 weeks
期刊介绍: Blood Coagulation & Fibrinolysis is an international fully refereed journal that features review and original research articles on all clinical, laboratory and experimental aspects of haemostasis and thrombosis. The journal is devoted to publishing significant developments worldwide in the field of blood coagulation, fibrinolysis, thrombosis, platelets and the kininogen-kinin system, as well as dealing with those aspects of blood rheology relevant to haemostasis and the effects of drugs on haemostatic components
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信